DUAKLIR PRESSAIR

Peak

aclidinium bromide and formoterol fumarate

NDAINHALATIONPOWDER, METERED
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2

Mechanism of Action

bronchodilators: aclidinium a long-acting muscarinic antagonist (also known as an anticholinergic) and formoterol a long-acting beta 2 -adrenergic agonist. Further information regarding these two substances is provided below. The mechanism of action described below for the individual components…

Clinical Trials (2)

NCT01437397Phase 3Completed

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Started Sep 2011
1,692 enrolled
Chronic Obstructive Pulmonary Disease
NCT00706914Phase 2Terminated

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Started Jun 2008
156 enrolled
Pulmonary Disease, Chronic Obstructive

Loss of Exclusivity

LOE Date
Mar 13, 2029
36 months away
Patent Expiry
Mar 13, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
10085974
Mar 13, 2029
Product
U-2513
11000517
Mar 13, 2029
Product
U-2513